Clinical Research Directory

Inclusion Criteria: Study population (exposed-patients), all criteria should be fulfilled: 1. Patients alive with Sickle Cell Anemia (SCA, meaning SS and Sbeta0 sickle cell anemia genotype) 2. Patients transplanted from allogeneic HLA-compatible sibling donor or from sibling cord blood unit from the 1st of January 2000 and the 31st of December 2012, whatever the age at transplant 3. Patients having received conditioning regimen containing busulfan 1mg/kg/dose (or equivalent adjusted body-weight dosage according to recommendation) x 16 doses + cyclophosphamide 200mg/kg total dose + anti-thymoglobuline 4. For patient under 18 years at time of enrolment, signed informed consent from both parental representatives 5. For patient aged 18 years old : signed informed consent 6. Having an affiliation to a social security regime Control-population (Non-exposed patients) : For each allografted patient, one non-exposed patient will be matched, based on the following criteria: * Gender * Age at the date of transplantation of the exposed patient (+/- 1 year) * Foetal hemoglobin (HbF) level (+/- 3%) before treatment intensification (defined as the initiation of either hydroxyurea or a transfusion program) * Hb level (+/- 0,9 g/dl) before treatment intensification 1. For patient under 18 years at time of enrolment, signed informed consent from both parental representatives 2. For patient above 18 years of age: signed informed consent 3. Having an affiliation of to a social security regime Exclusion Criteria: Study population: * Transplantation from donor other than sibling or related cord-blood * Conditioning regimen other than busulfan 16mg/kg total dose + cyclophosphamide 200mg/kg total dose + anti-thymoglobuline For both population: * Absence of signed informed consent * Having any debilitating medical or psychiatric illness, which preclude understanding of the inform consent as well as optimal treatment and follow-up